Skip to main content
ENDO 2026 Main banner

Diabetes and Vascular Disease

SY27-01 - Delaying the Onset of Type 1 Diabetes: Teplizumab and Beyond

Sunday, June 14, 2026
10:30 AM - 10:52 AM CT
Disclosure(s):
Carmella Evans-Molina, MD, PhD: Astellas Pharmaceuticals: Grant Recipient (); Bristol Myers Squibb: In-Kind research support (); DiogenyX: Advisory Board (); Excalibur: Honorarium Recipient (); Isla Technologies: Advisory Board (); Lilly Pharmaceuticals: Grant Recipient (); Neurodon: Advisory Board (); Patent 16/291,668) Extracellular Vesicle Ribonucleic Acid (RNA) Cargo as a Biomarker of Hyperglycemia and Type 1 Diabetes : Patent (); Provisional Patent (63/285,765) Biomarker for Type 1 Diabetes (PDIA1 as a biomarker of β cell stress) : Provisional patent (); Sanofi: Advisory Board ()